Effectiveness of the ten-valent pneumococcal conjugate vaccine against tympanostomy tube placements in a cluster-randomized trial

Pediatric Infectious Disease Journal

Volumn 34, Issue 11, 2015, Pages 1230-1235

  Palmu, Arto A ^a   Jokinen, Jukka ^a   Nieminen, Heta ^a   Rinta Kokko, Hanna ^a   Ruokokoski, Esa ^a   Puumalainen, Taneli ^b   Traskine, Magali ^c   Moreira, Marta ^c   Borys, Dorota ^c   Schuerman, Lode ^c   Kilpi, Terhi M ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b GLAXOSMITHKLINE   (Finland)

^c GSK   (Belgium)

Author keywords

Clinical trial; Infant; Pneumococcus; Tympanostomy; Vaccine

Indexed keywords

HEPATITIS A VACCINE; HEPATITIS B VACCINE; PNEUMOCOCCAL HEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE VACCINE; PNEUMOCOCCUS VACCINE; UNCLASSIFIED DRUG; VACCINE;

ARTICLE; CHILD; CLUSTER ANALYSIS; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE REGISTRY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FOLLOW UP; GROUPS BY AGE; HUMAN; INCIDENCE; INFANT; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REIMBURSEMENT; TYMPANOSTOMY TUBE; VACCINATION; CLINICAL TRIAL; IMMUNIZATION; IMMUNOLOGY; MIDDLE EAR VENTILATION; NEWBORN; PHASE 3 CLINICAL TRIAL; PHASE 4 CLINICAL TRIAL; PRESCHOOL CHILD; STATISTICS AND NUMERICAL DATA;

CHILD, PRESCHOOL; HUMANS; IMMUNIZATION SCHEDULE; INFANT; INFANT, NEWBORN; MIDDLE EAR VENTILATION; PNEUMOCOCCAL VACCINES; VACCINATION; VACCINES, CONJUGATE;

EID: 84944254979     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000857     Document Type: Article

References (21)

1. Rosenfeld RM, Schwartz SR, Pynnonen MA et al. Clinical practice guideline: Tympanostomy tubes in children. Otolaryngol Head Neck Surg. 2013;149:S1-35.
2. Desai SN, Kellner JD, Drummond D. Population-based, age-specific myringotomy with tympanostomy tube insertion rates in Calgary, Canada. Pediatr Infect Dis J. 2002;21:348-350.
3. Haapkylä J, Karevold G, Kvaerner KJ, et al. Trends in otitis media surgery: A decrease in adenoidectomy. Int J Pediatr Otorhinolaryngol. 2008;72: 1207-1213.
4. Cullen KA, Hall MJ, Golosinskiy A. Ambulatory surgery in the United States, 2006. Natl Health Stat Report. 2009;11:1-25.
5. Fireman B, Black SB, Shinefield HR, et al. Impact of the pneumococcal conjugate vaccine on otitis media. Pediatr Infect Dis J. 2003;22:10-16.
6. Palmu AA, Verho J, Jokinen J, et al. The seven-valent pneumococcal conjugate vaccine reduces tympanostomy tube placement in children. Pediatr Infect Dis J. 2004;23:732-738.
7. Sarasoja I, Jokinen J, Lahdenkari M, et al. Long-term effect of pneumococcal conjugate vaccines on tympanostomy tube placements. Pediatr Infect Dis J. 2013;32:517-520.
8. Poehling KA, Szilagyi PG, Grijalva CG, et al. Reduction of frequent otitis media and pressure-equalizing tube insertions in children after introduction of pneumococcal conjugate vaccine. Pediatrics. 2007;119:707-715.
9. Jardine A, Menzies RI, Deeks SL, et al. The impact of pneumococcal conjugate vaccine on rates of myringotomy with ventilation tube insertion in Australia. Pediatr Infect Dis J. 2009;28:761-765.
10. Marom T, Tan A, Wilkinson GS, et al. Trends in otitis media-related health care use in the United States, 2001-2011. JAMA Pediatr 2014;168: 68-75.
11. Palmu AA, Jokinen J, Borys D, et al. Effectiveness of the ten-valent pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) against invasive pneumococcal disease: A cluster randomised trial. Lancet. 2013;381:214-222.
12. Palmu AA, Jokinen J, Nieminen H, et al. Vaccine effectiveness of the pneumococcal Haemophilus influenzae protein D conjugate vaccine against clinically suspected non-laboratory-confirmed invasive pneumococcal disease in a cluster-randomized trial. Lancet Resp Med. 2014;2:717-727.
13. Palmu AA, Jokinen J, Nieminen H, et al. Effect of pneumococcal Haemophilus influenzae protein D conjugate vaccine (PHiD-CV10) on outpatient antimicrobial purchases: A double-blind, cluster randomised phase 3-4 trial. Lancet Infect Dis. 2014;14:205-212.
14. Vesikari T, Forstén A, Seppä I, et al. Immunogenicity and safety of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in healthy Finnish infants and toddlers. In: ESPID 2013, Milan, Italy, May 28 to June 1, 2013.
15. Donner A, Klar N. Design and Analysis of Cluster Randomization Trials in Health Research. London: Arnold; 2000.
16. Oehlert GW. A note on the delta method. Am Statist. 1992;46: 27-29.
17. Prymula R, Peeters P, Chrobok V, et al. Pneumococcal capsular polysaccharides conjugated to protein D for prevention of acute otitis media caused by both Streptococcus pneumoniae and non-typeable Haemophilus influenzae: A randomised double-blind efficacy study. Lancet. 2006;367: 740-748.
18. Black S, Shinefield H, Fireman B, et al. Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J. 2000;19:187-195.
19. Haapkylä J, Karevold G, Kvaerner KJ, et al. Finnish adenoidectomy and tympanostomy rates in children; national variation. Int J Pediatr Otorhinolaryngol. 2006;70:1569-1573.
20. Karevold G, Haapkylä J, Pitkäranta A, et al. Otitis media surgery: large variability between Finland and Norway. Int J Pediatr Otorhinolaryngol. 2007;71:1035-1039.
21. Working Group Appointed by the Finnish Medical Society Duodecim, the Finnish Paediatric Society, the Finnish Otolaryngological Society and the Finnish Association for General Practice. Otitis media (acute). Current Care Guideline. Duodecim, Helsinki: Finnish Medical Society; 2010. Available at: http://www.kaypahoito.fi/Accessed January 7, 2015.